

# **Inject PrEP to protect?**

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



# What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.


The European Commission (EC) has authorized Apretude ® (cabotegravir longacting [LA] injectable and tablets) for HIV prevention. It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.

This factsheet reports on data from the PROTECT Survey collected in Denmark from men who have sex with men N= 197.

**PROTECH** Maastricht University



### SEXUAL ORIENTATION




PROTECH 🛛 🏷 Maastricht University


AGE



#### MIGRANT STATUS



#### **RELATIONSHIP STATUS**



■ Single, not dating: 35	
■ Single, dating: 64	
■In a relationship: 51	

In an open/polyamorous


An adequate representation of MSM in **Denmark!** 

Maastricht University



#### CHEMSEX (in the past 6 months)

#### NUMBER OF SEXUAL PARTNERS (in the past 6 months)





#### **Example of campaign image**

Maastricht University

Det finnes en ny måte å ta PrEP på via en langtidsvirkende sprøyte. Vi gjennomfører en undersøkelse for å se om folk som deg vil være interessert i dette. Bli hørt, og ta den korte undersøkelsen!



Mer informasjon >



38%

6%

27%


10%

19%

- More than every 6 months: 74
- Every 6 months: 54
- Less than once a year: 38
- ■Once a year: 20
- ■Never: 11

#### **ORAL PREP USE HISTORY & CURRENT PREP REGIMEN**

#### Naive: 82 Current: 108 Former: 7





PROTECH

#### AWARENESS OF ORAL PrEP

Maastricht University

#### CURRENT PREP USERS – ACCESS TO ORAL PREP

0%

Activist

group.

Buyers club


0

0%

Informal

access

0



29 August 2024 Page 7

0%

Other

0

### **Barriers to oral PrEP use**

- 8% of the MSM said:
  - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- 9% of the MSM said:
  - The procedure took too long to obtain oral PrEP when they needed it
- 19% of the MSM said:
  - Their healthcare provider did not offer oral PrEP to them
- 7% of the MSM said:
  - There was a waiting list at their healthcare provider for oral PrEP and the service was not available



### Long-acting PrEP: interest and intention

## **69%**

are interested in using LA-PrEP if it becomes available.

### 74%

intend to use LA-PrEP if it becomes available.

Different PrEP modalities are needed!

PROTECH 🛛 🏷 Maastricht University

### What LA-PrEP could mean to participants

This word cloud was generated from responses that participants provided to a question asking them what LA-PrEP could mean to them, if it were to become available.

ved 😾 **Ke**safety hed <sup>E</sup>nemtjeg č freedom mere easier

# Summary & Contact Information

### SUMMARY

- Danish MSM are aware of PrEP and have taken up oral PrEP
- Barriers to starting PrEP still exist
- Interest and intention to use LA-PrEP among MSM in Denmark is high
- LA-PrEP may provide an opportunity for greater HIV prevention in Denmark

### **CONTACT INFORMATION**

- Prof. Dr. Kai J. Jonas
  Email: kai.jonas@maastrichtuniversity.nl
- Dr. Johann Kolstee Email: johann.kolstee@maastrichtuniversity.nl
- Maastricht University postal address
  P.O. Box 616, 6200 MD Maastricht, The Netherlands